|
End-of-day quote
Korea S.E.
02/10/2026
|
5-day change | 1st Jan Change | ||
| 15,710.00 KRW | -1.32% |
|
+3.83% | -19.64% |
| 09-21 | Onconic Therapeutics Inc.(KOSDAQ:A476060) added to S&P Global BMI Index | CI |
| 30/10/25 | Onconic Therapeutics Q3 operating profit 8.3 billion won, swings to profit from year earlier | RE |
Company Valuation: Onconic Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
| Market Cap 1 | 176,537 | 869,777 |
| Change | - | 392.69% |
| Enterprise Value (EV) 1 | 133,846 | 817,168 |
| Change | - | 510.53% |
| P/E | -16.5x | 56.2x |
| PBR | 3.15x | 12.1x |
| PEG | 0x | -0x |
| Capitalization / Revenue | 11.9x | 16.3x |
| EV / Revenue | 9.02x | 15.3x |
| EV / EBITDA | -30.8x | 62.2x |
| EV / EBIT | -27.9x | 64.8x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Dividend per Share 2 | - | - |
| Rate of return | - | - |
| EPS 2 | -247.5 | 347.9 |
| Distribution rate | - | - |
| Net sales 1 | 14,838 | 53,392 |
| EBITDA 1 | -4,345 | 13,148 |
| EBIT 1 | -4,798 | 12,619 |
| Net income 1 | -8,093 | 15,784 |
| Net Debt 1 | -42,691 | -52,609 |
| Reference price 2 | 4,085.00 | 19,550.00 |
| Nbr of stocks (in thousands) | 43,216 | 44,490 |
| Announcement Date | 01/03/25 | 01/03/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 530M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 20.98x | 31.37x | 12.47x | 0.31% | 39.11B | |
| Weighted average by Cap. | 22.27x | 32.04x | 13.55x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A476060 Stock
- Valuation Onconic Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
